The Role of the Surgeon in the Germline Testing of the Newly Diagnosed Breast Cancer Patient
Abstract
1. Introduction
2. Materials and Methods
3. Results
3.1. The Prevalence of Germline Mutations in Breast Cancer Patients
3.2. The Benefits of Testing—How Does Genetic Testing Alter Clinical Decision-Making?
3.2.1. Local Therapy Decisions
3.2.2. The Risk of Contralateral Breast Cancer
3.2.3. The Impact on Systemic Therapy
4. Discussion
5. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Clark, N.M.; Roberts, E.A.; Fedorenko, C.; Sun, Q.; Dubard-Gault, M.; Handford, C.; Yung, R.; Cheng, H.H.; Sham, J.G.; Norquist, B.M.; et al. Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers. Ann. Surg. Oncol. 2022, 30, 1312–1326. [Google Scholar] [CrossRef]
- Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Version 3.2023. Available online: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf (accessed on 26 February 2023).
- O’Leary, E.; Iacoboni, D.; Holle, J.; Michalski, S.T.; Esplin, E.D.; Yang, S.; Ouyang, K. Expanded Gene Panel Use for Women with Breast Cancer: Identification and Interven-tion Beyond Breast Cancer Risk. Ann. Surg. Oncol. 2017, 24, 3060–3066. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Tung, N.; Lin, N.U.; Kidd, J.; Allen, B.A.; Singh, N.; Wenstrup, R.J.; Hartman, A.-R.; Winer, E.P.; Garber, J.E. Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients with Breast Cancer. J. Clin. Oncol. 2016, 34, 1460–1468. [Google Scholar] [CrossRef][Green Version]
- Buys, S.S.; Sandbach, J.F.; Gammon, A.; Patel, M.; Kidd, J.; Brown, K.L.; Sharma, L.; Saam, J.; Lancaster, J.; Daly, M.B. A Study of Over 35,000 Women with Breast Cancer Tested with A 25-Gene Panel of Hereditary Cancer Genes. Cancer 2017, 123, 1721–1730. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Beitsch, P.D.; Whitworth, P.W.; Hughes, K.; Patel, R.; Rosen, B.; Compagnoni, G.; Baron, P.; Simmons, R.; Smith, L.A.; Grady, I.; et al. Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle? J. Clin. Oncol. 2019, 37, 453–460. [Google Scholar] [CrossRef]
- Hu, C.; Hart, S.N.; Gnanaolivu, R.; Huang, H.; Lee, K.Y.; Na, J.; Gao, C.; Lilyquist, J.; Yadav, S.; Boddicker, N.J.; et al. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N. Engl. J. Med. 2021, 384, 440–451. [Google Scholar] [CrossRef] [PubMed]
- Kurian, A.W.; Ward, K.C.; Howlader, N.; Deapen, D.; Hamilton, A.S.; Mariotto, A.; Miller, D.; Penberthy, L.S.; Katz, S.J. Genetic Testing and Results in a Population-Based Co-hort of Breast Cancer Patients and Ovarian Cancer Patients. J. Clin. Oncol. 2019, 37, 1305–1315. [Google Scholar] [CrossRef][Green Version]
- Tung, N.; Batteli, C.; Allen, B.; Kaldate, R.; Bhatnagar, S.; Bowles, K.; Timms, K.; Garber, J.E.; Herold, C.; Ellisen, L.; et al. Frequency of Mutations in Individuals with Breast Cancer Referred for BRCA1 And BRCA2 Testing Using Next-Generation Sequencing with A 25-Gene Panel. Cancer 2015, 121, 25–33. [Google Scholar] [CrossRef]
- Pritzlaff, M.; Summerour, P.; McFarland, R.; Li, S.; Reineke, P.; Dolinsky, J.S.; Goldgar, D.E.; Shimelis, H.; Couch, F.J.; Chao, E.C.; et al. Male Breast Cancer in A Multi-Gene Panel Testing Cohort: In-Sights and Unexpected Results. Breast Cancer Res. Treat. 2017, 161, 575–586. [Google Scholar] [CrossRef][Green Version]
- Rolfes, M.; Borde, J.; Möllenhoff, K.; Kayali, M.; Ernst, C.; Gehrig, A.; Sutter, C.; Ramser, J.; Niederacher, D.; Horváth, J.; et al. Prevalence of Cancer Predisposition Germline Variants in Male Breast Cancer Patients: Results of the German Consortium for Hereditary Breast and Ovarian Cancer. Cancers 2022, 14, 3292. [Google Scholar] [CrossRef]
- Yang, S.; Axilbund, J.E.; O’Leary, E.; Michalski, S.T.; Evans, R.; Lincoln, S.E.; Esplin, E.D.; Nussbaum, R.L. Underdiagnosis of Hereditary Breast and Ovarian Cancer in Medicare Patients: Genetic Testing Criteria Miss the Mark. Ann. Surg. Oncol. 2018, 25, 2925–2931. [Google Scholar] [CrossRef]
- Consensus Guideline on Genetic Testing for Hereditary Breast Cancer. Version 2019. Available online: https://www.breastsurgeons.org/docs/statements/Consensus-Guideline-on-Genetic-Testing-for-Hereditary-Breast-Cancer.pdf (accessed on 25 February 2023).
- Yadav, S.; Hu, C.; Hart, S.N.; Boddicker, N.; Polley, E.C.; Na, J.; Gnanaolivu, R.; Lee, K.Y.; Lindstrom, T.; Armasu, S.; et al. Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women with Breast Cancer. J. Clin. Oncol. 2020, 38, 1409–1418. [Google Scholar] [CrossRef]
- Valachis, A.; Nearchou, A.D.; Lind, P. Surgical management of breast cancer in BRCA-mutation carriers: A systematic review and meta-analysis. Breast Cancer Res. Treat. 2014, 144, 443–455. [Google Scholar] [CrossRef]
- Co, M.; Liu, T.; Leung, J.; Li, C.H.; Tse, T.; Wong, M.; Kwong, A. Breast Conserving Surgery for BRCA Mutation Carriers-A System-atic Review. Clin. Breast Cancer 2020, 20, e244–e250. [Google Scholar] [CrossRef] [PubMed]
- Tung, N.M.; Boughey, J.C.; Pierce, L.J.; Robson, M.E.; Bedrosian, I.; Dietz, J.R.; Dragun, A.; Gelpi, J.B.; Hofstatter, E.W.; Isaacs, C.J.; et al. Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. J. Clin. Oncol. 2020, 38, 2080–2106. [Google Scholar] [CrossRef]
- Mai, P.L.; Best, A.F.; Peters, J.A.; DeCastro, R.M.; Khincha, P.P.; Loud, J.T.; Bremer, R.C.; Rosenberg, P.S.; Savage, S.A. Risks of First and Subsequent Cancers among TP53 Mutation Car-Riers in The National Cancer Institute Li-Fraumeni Syndrome Cohort. Cancer 2016, 122, 3673–3681. [Google Scholar] [CrossRef][Green Version]
- Guo, Y.; Wan, Q.; Ouyang, T.; Li, J.; Wang, T.; Fan, Z.; Xie, Y. Risk of ipsilateral breast tumor recurrence and contralateral breast cancer in patients with and without TP53 variant in a large series of breast cancer patients. Breast 2022, 65, 55–60. [Google Scholar] [CrossRef] [PubMed]
- Heymann, S.; Delaloge, S.; Rahal, A.; Caron, O.; Frebourg, T.; Barreau, L.; Pachet, C.; Mathieu, M.-C.; Marsiglia, H.; Bourgier, C. Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat. Oncol. 2010, 5, 104. [Google Scholar] [CrossRef][Green Version]
- Gondim, G.R.M.; Formiga, M.N.C.; Castro, D.G.; Silva, M.L.G.; Chen, M.; Fogaroli, R.; Ramos, H.; Coelho, T.M.; Pellizzon, A.C.A.; Da Costa, A.A.B.A. Adjuvant radiation therapy in patients with breast cancer and Li-Fraumeni syndrome: Oncologic results and incidence of second neoplasms. J. Clin. Oncol. 2018, 36, e12589. [Google Scholar] [CrossRef]
- Le, A.N.; Harton, J.; Desai, H.; Powers, J.; Zelley, K.; Bradbury, A.R.; Nathanson, K.L.; Shah, P.D.; Doucette, A.; Freedman, G.M.; et al. Frequency of Radiation-Induced Malignancies Post-Adjuvant Radiothera-Py for Breast Cancer in Patients with Li-Fraumeni Syndrome. Breast Cancer Res. Treat. 2020, 181, 181–188. [Google Scholar] [CrossRef] [PubMed]
- Bergstrom, C.; Pence, C.; Berg, J.; Partain, N.; Sadeghi, N.; Mauer, C.; Pirzadeh-Miller, S.; Gao, A.; Li, H.; Unni, N.; et al. Clinicopathological Features and Outcomes in Individuals with Breast Cancer and ATM, CHEK2, or PALB2 Mutations. Ann. Surg. Oncol. 2020, 28, 3383–3393. [Google Scholar] [CrossRef] [PubMed]
- Meyer, A.; Dörk, T.; Sohn, C.; Karstens, J.H.; Bremer, M. Breast cancer in patients carrying a germ-line CHEK2 mutation: Outcome after breast conserving surgery and adjuvant radiotherapy. Radiother. Oncol. 2007, 82, 349–353. [Google Scholar] [CrossRef] [PubMed]
- Chapman, B.V.; Liu, D.; Shen, Y.; Olamigoke, O.O.; Lakomy, D.S.; Barrera, A.M.G.; Stecklein, S.R.; Sawakuchi, G.O.; Bright, S.J.; Bedrosian, I.; et al. Breast Radiation Therapy–Related Treatment Outcomes in Patients with or Without Germline Mutations on Multigene Panel Testing. Int. J. Radiat. Oncol. 2021, 112, 437–444. [Google Scholar] [CrossRef]
- McDuff, S.G.R.; Bellon, J.R.; Shannon, K.M.; Gadd, M.A.; Dunn, S.; Rosenstein, B.S.; Ho, A.Y. ATM Variants in Breast Cancer: Implica-tions for Breast Radiation Therapy Treatment Recommendations. Int. J. Radiat. Oncol. Biol. Phys. 2021, 110, 1373–1382. [Google Scholar] [CrossRef] [PubMed]
- Robson, M. Management of Women with Breast Cancer and Pathogenic Variants in Genes Other Than BRCA1 or BRCA2. J. Clin. Oncol. 2021, 39, 2528–2534. [Google Scholar] [CrossRef] [PubMed]
- Yadav, S.; Boddicker, N.J.; Na, J.; Polley, E.C.; Hu, C.; Hart, S.N.; Gnanaolivu, R.D.; Larson, N.; Holtegaard, S.; Huang, H.; et al. Contralateral Breast Cancer Risk among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. J. Clin. Oncol. 2023, 41, 1703–1713. [Google Scholar] [CrossRef]
- Mellemkjær, L.; The WECARE Study Collaborative Group; Dahl, C.; Olsen, J.H.; Bertelsen, L.; Guldberg, P.; Christensen, J.; Børresen-Dale, A.-L.; Stovall, M.; Langholz, B.; et al. Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study. Br. J. Cancer 2008, 98, 728–733. [Google Scholar] [CrossRef]
- Graeser, M.K.; Engel, C.; Rhiem, K.; Gadzicki, D.; Bick, U.; Kast, K.; Froster, U.G.; Schlehe, B.; Bechtold, A.; Arnold, N.; et al. Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. J. Clin. Oncol. 2009, 27, 5887–5892. [Google Scholar] [CrossRef]
- Hyder, Z.; Harkness, E.F.; Woodward, E.R.; Bowers, N.L.; Pereira, M.; Wallace, A.J.; Howell, S.J.; Howell, A.; Lalloo, F.; Newman, W.G.; et al. Risk of Contralateral Breast Cancer in Women with and without Pathogenic Variants in BRCA1, BRCA2, and TP53 Genes in Women with Very Early-Onset (<36 Years) Breast Cancer. Cancers 2020, 12, 378. [Google Scholar] [CrossRef][Green Version]
- Teoh, V.; Tasoulis, M.K.; Gui, G. Contralateral Prophylactic Mastectomy in Women with Unilateral Breast Cancer Who Are Ge-netic Carriers, have a Strong Family History or Are just Young at Presentation. Cancers 2020, 12, 140. [Google Scholar] [CrossRef][Green Version]
- van Sprundel, T.C.; Schmidt, M.K.; Rookus, M.A.; Brohet, R.; van Asperen, C.J.; Rutgers, E.J.; Van’t Veer, L.J.; Tollenaar, R.A. Risk Reduction of Contralateral Breast Cancer and Survival after Contralateral Prophylactic Mastectomy in BRCA1 or BRCA2 Mutation Carriers. Br. J. Cancer. 2005, 93, 287–292. [Google Scholar] [CrossRef] [PubMed][Green Version]
- E Carbine, N.; Lostumbo, L.; Wallace, J.; Ko, H. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst. Rev. 2018, 2019, CD002748. [Google Scholar] [CrossRef]
- Kurian, A.W.; Ward, K.C.; Abrahamse, P.; Hamilton, A.S.; Deapen, D.; Morrow, M.; Jagsi, R.; Katz, S.J. Association of Germline Genetic Testing Results with Locoregional and Systemic Therapy in Patients With Breast Cancer. JAMA Oncol. 2020, 6, e196400. [Google Scholar] [CrossRef] [PubMed]
- Chiba, A.; Hoskin, T.L.; Hallberg, E.J.; Cogswell, J.A.; Heins, C.N.; Couch, F.J.; Boughey, J.C. Impact that Timing of Genetic Mutation Diagnosis Has on Surgical Decision Making and Outcome for BRCA1/BRCA2 Mutation Carriers with Breast Cancer. Ann. Surg. Oncol. 2016, 23, 3232–3238. [Google Scholar] [CrossRef][Green Version]
- Cortesi, L.; Rugo, H.S.; Jackisch, C. An Overview of PARP Inhibitors for the Treatment of Breast Cancer. Target. Oncol. 2021, 16, 255–282. [Google Scholar] [CrossRef]
- Robson, M.; Im, S.A.; Senkus, E.; Xu, B.; Domchek, S.M.; Masuda, N.; Delaloge, S.; Li, W.; Tung, N.; Armstrong, A.; et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N. Engl. J. Med. 2017, 377, 523–533. [Google Scholar] [CrossRef]
- Litton, J.K.; Rugo, H.S.; Ettl, J.; Hurvitz, S.A.; Gonçalves, A.; Lee, K.-H.; Fehrenbacher, L.; Yerushalmi, R.; Mina, L.A.; Martin, M.; et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N. Engl. J. Med. 2018, 379, 753–763. [Google Scholar] [CrossRef] [PubMed]
- FDA Approves Olaparib for Adjuvant Treatment of High-Risk Early Breast Cancer. Available online: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-adjuvant-treatment-high-risk-early-breast-cancer (accessed on 10 February 2023).
- rtmański, S.; Metcalfe, K.; TrempaŁa, J.; Głowacka, M.D.; Lubiński, J.; Narod, S.A.; Gronwald, J. Identification of Patients at High Risk of Psychological Distress After BRCA1 Genetic Testing. Genet. Test. Mol. Biomarkers 2009, 13, 325–330. [Google Scholar] [CrossRef]
- Makhnoon, S.; Bednar, E.M.; Krause, K.J.; Peterson, S.K.; Lopez-Olivo, M.A. Clinical Management among Individuals with Variant of Uncertain Significance in Hereditary Cancer: A Systematic Review and Meta-Analysis. Clin. Genet. 2021, 100, 119–131. [Google Scholar] [CrossRef]
- Plichta, J.K.; Sebastian, M.L.; Smith, L.A.; Menendez, C.S.; Johnson, A.T.; Bays, S.M.; Euhus, D.M.; Clifford, E.J.; Jalali, M.; Kurtzman, S.H.; et al. Germline Genetic Testing: What the Breast Surgeon Needs to Know. Ann. Surg. Oncol. 2019, 26, 2184–2190. [Google Scholar] [CrossRef]
- Kiechle, M.; Engel, C.; Berling, A.; Hebestreit, K.; Bischoff, S.; Dukatz, R.; Gerber, W.D.; Siniatchkin, M.; Pfeifer, K.; Grill, S.; et al. Lifestyle Intervention in BRCA1/2 Mutation Carriers: Study Protocol for A Prospective, Randomized, Controlled Clinical Feasibility Trial (LIBRE-1 Study). Pilot. Feasibil. Study 2016, 2, 74. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Stenehjem, D.D.; Au, T.; Sainski, A.M.; Bauer, H.; Brown, K.; Lancaster, J.; Stevens, V.; Brixner, D.I. Impact of a genetic counseling requirement prior to genetic testing. BMC Health Serv. Res. 2018, 18, 1–11. [Google Scholar] [CrossRef][Green Version]
- National Society of Genetic Counselors Executive Summary. April 2021. Available online: https://www.nsgc.org/Portals/0/Executive%20Summary%202021%20FINAL%2005-03-21.pdf (accessed on 21 February 2023).
- Bracke, X.; Roberts, J.; McVeigh, T.P. A Systematic Review and Meta-Analysis of Telephone Vs In-Person Genetic Counseling in BRCA1/BRCA2 Genetic Testing. J. Genet. Couns. 2021, 30, 563–573. [Google Scholar] [CrossRef] [PubMed]
- Zierhut, H.A.; MacFarlane, I.M.; Ahmed, Z.; Davies, J. Genetic Counselors’ Experiences and Interest in Telegenetics and Remote Counseling. J. Genet. Couns. 2018, 27, 329–338. [Google Scholar] [CrossRef] [PubMed]
- Cacioppo, C.N.; Egleston, B.L.; Fetzer, D.; Sands, C.B.; Raza, S.A.; Malleda, N.R.; Wood, E.M.; Rittenburg, I.; Childs, J.; Cho, D.; et al. Randomized study of remote telehealth genetic services versus usual care in oncology practices without genetic counselors. Cancer Med. 2021, 10, 4532–4541. [Google Scholar] [CrossRef]
- Brown, E.G.; Watts, I.; Beales, E.R.; Maudhoo, A.; Hayward, J.; Sheridan, E.; Rafi, I. Videoconferencing to deliver genetics services: A systematic review of telegenetics in light of the COVID-19 pandemic. Anesthesia Analg. 2021, 23, 1438–1449. [Google Scholar] [CrossRef]
- Ochoa, D.; Jean-Louis, C.; Stephenson, K.; Woods, M.; Kelsey, J.; Henry-Tillman, R. What happens after referral? Completion rates of genetic counseling evaluations in breast cancer patients. J. Natl. Med Assoc. 2022, 114, 90–93. [Google Scholar] [CrossRef]
- Culver, J.O.; Freiberg, Y.; Ricker, C.; Comeaux, J.G.; Chang, E.Y.; Banerjee, V.; Sturgeon, D.; Solomon, I.; Kagey, J.; Dobre, M.G.; et al. Integration of Universal Germline Genetic Testing for All New Breast Cancer Patients. Ann. Surg. Oncol. 2022, 30, 1017–1025. [Google Scholar] [CrossRef]
- Rana, H.Q.; Kipnis, L.; Hehir, K.; Cronin, A.; Jaung, T.; Stokes, S.M.; Fekrmandi, F.; Vatnick, D.; Matulonis, U.A.; Garber, J.E.; et al. Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancer. Gynecol. Oncol. 2020, 160, 457–463. [Google Scholar] [CrossRef]
- Optimal Resources for Breast Care 2024 Standards. Version February 2023. Available online: https://accreditation.facs.org/accreditationdocuments/NAPBC/Standards/Optimal_Resources_for_Breast_Care_2024.pdf (accessed on 26 February 2023).
- Optimal Resources for Cancer Care 2020 Standards. Version April 2023. Available online: https://www.facs.org/media/whmfnppx/2020_coc_standards.pdf (accessed on 26 February 2023).
- Robson, M.E.; Bradbury, A.R.; Arun, B.; Domchek, S.M.; Ford, J.M.; Hampel, H.L.; Lipkin, S.M.; Syngal, S.; Wollins, D.S.; Lindor, N.M. American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. J. Clin. Oncol. 2015, 33, 3660–3667. [Google Scholar] [CrossRef][Green Version]
- Ain, Q.; Richardson, C.; Mutebi, M.; George, A.; Kemp, Z.; Rusby, J.E. Does Mainstream BRCA Testing Affect Surgical Decision-Making in Newly Diagnosed Breast Cancer Patients? Breast 2023, 67, 30–35. [Google Scholar] [CrossRef] [PubMed]
- Beitsch, P.D.; Whitworth, P.W. Can Breast Surgeons Provide Breast Cancer Genetic Testing? An American Society of Breast Sur-geons survey. Ann. Surg. Oncol. 2014, 21, 4104–4108. [Google Scholar] [CrossRef] [PubMed]
- Genetics and Genomics. Available online: https://education.asco.org/coursecollection/genetics-and-genomics (accessed on 26 February 2023).
- Bringing Genetic Testing into Your Clinic. Available online: https://www.breastsurgeons.org/meeting/2023/pre/genetic (accessed on 26 February 2023).
- Intensive Course in Genetic Cancer Risk Assessment 2023. Available online: https://www.cityofhope.org/academics/health-professional-education/cancer-genomics-education-program/intensive-course-in-cancer-risk-assessment-overview (accessed on 26 February 2023).
Individual with blood relative with PV/LPV in cancer susceptibility gene |
Individuals who previously tested negative by limited testing panel |
Breast cancer diagnosis ≤ age 50 |
Male breast cancer regardless of age |
Triple negative histology regardless of age |
Ashkenazi Jewish ancestry regardless of age |
Lobular histology with personal or family history of diffuse gastric cancer |
Multiple breast primaries |
High risk cancers who may be considered candidates for molecular targeted agents |
Metastatic breast cancers |
Personal history of breast cancer with close family members with breast cancer ≤ age 50, ovarian cancer, prostate cancer, male breast cancer, pancreatic cancer |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Schick, S.; Manghelli, J.; Ludwig, K.K. The Role of the Surgeon in the Germline Testing of the Newly Diagnosed Breast Cancer Patient. Curr. Oncol. 2023, 30, 4677-4687. https://doi.org/10.3390/curroncol30050353
Schick S, Manghelli J, Ludwig KK. The Role of the Surgeon in the Germline Testing of the Newly Diagnosed Breast Cancer Patient. Current Oncology. 2023; 30(5):4677-4687. https://doi.org/10.3390/curroncol30050353
Chicago/Turabian StyleSchick, Stephanie, Joshua Manghelli, and Kandice K. Ludwig. 2023. "The Role of the Surgeon in the Germline Testing of the Newly Diagnosed Breast Cancer Patient" Current Oncology 30, no. 5: 4677-4687. https://doi.org/10.3390/curroncol30050353
APA StyleSchick, S., Manghelli, J., & Ludwig, K. K. (2023). The Role of the Surgeon in the Germline Testing of the Newly Diagnosed Breast Cancer Patient. Current Oncology, 30(5), 4677-4687. https://doi.org/10.3390/curroncol30050353